ScreenerHero
HPHAHeidelberg Pharma AG
XETRA · DE · Healthcare · Biotechnology · heidelberg-pharma.com
2.460EUR-2.38%Mkt Cap: 125.10M $P/E: —

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candid…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap125.10M $
Enterprise Value101.10M $
Revenue (TTM)8.09M $
Gross Profit1.29M $
Net Income (TTM)-45.96M $
Revenue/Share0.1728 USD
Last Price2.460 EUR
Fiscal Year EndDec 2019
MR QuarterMay 2026
Employees41
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A11QVV0
Valuation
P/E (Trailing)—
P/E (Forward)-5.14
PEG5.46
EV/EBITDA-2.52
EV/Revenue12.49
P/S16.21
P/B-8.49
EPS (TTM)-0.71
EPS (Forward)-0.50
52W Range
2.3306% of range4.640
52W High4.640 EUR
52W Low2.330 EUR
Profitability
Gross Margin81.31%
Oper. Margin3.32%
EBITDA Margin0.00%
Profit Margin-2901.15%
ROE387.26%
ROA-110.87%
Growth
Revenue Growth3566.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-34.35M $
CapEx (TTM)146.79K $
FCF Margin-253.46%
FCF Yield-16.40%
Net Debt-27.05M $
Net Debt/EBITDA0.68
Balance Sheet
Debt/Equity-0.01
Current Ratio5.29
Quick Ratio3.78
Book Value/Sh-0.3040 EUR
Cash/Share0.5330 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJul 18, 2014
Analyst Consensus
Rating—
Target (Mean)6.750 EUR
Upside (mean)+174.4%
Target Range5.500 EUR – 8.000 EUR
€5.500+174.4% to mean€8.000
# Analysts2
Ownership
Shares Out.46.78M
Float9.97M
Insiders79.00%
Institutions1.73%
Technical
SMA 502.577 (-4.5%)
SMA 2002.783 (-11.6%)
Beta0.77
S&P 52W Chg18.16%
Avg Vol (30d)3.21K
Avg Vol (10d)2.79K
Technical Indicators
RSI (14)46.7
MACD-0.0178
MACD Signal-0.0189
MACD Hist.+0.0011
BB Upper2.653 EUR
BB Middle2.550 EUR
BB Lower2.447 EUR
BB Width8.11%
ATR (14)0.1026 EUR
Vol Ratio (20d)0.17x